UK-based liquid biopsy company ANGLE plc has won a pharma services contract worth up to $1.2 million from an undisclosed pharma company that is engaged in developing cancer drugs.

The pharma company has chosen ANGLE’s Parsortix system to carry out longitudinal monitoring of patients in three separate clinical trials in prostate cancer and other locally advanced and metastatic solid tumors to be held globally.

The contract duration will be nearly 18 months.

According to ANGLE, the work pertains to a large phase 3 prostate cancer study and a couple of smaller phase 1 studies.

If successful, the phase 1 studies could advance to larger phase 2 studies and subsequently to much larger phase 3 studies, said the liquid biopsy company.

ANGLE said that its pharma services contract include the capture, harvesting, and analysis of circulating tumor cells (CTCs) and CTC clusters. The company said that samples are being shipped from various study centers to its clinical laboratories in the UK and the US for getting analyzed with the Parsortix system.

Andrew Newland – ANGLE Founder and Chief Executive said: “We are delighted to have contracted with a pharma company developing numerous cancer drugs and look forward to working closely with them on their trials. ANGLE believes that there is a substantial business opportunity in providing services to pharma and biotech customers to support cancer drug trials.

“This contract demonstrates that our investment in clinical laboratories and a pharma services business, a key use of proceeds from our fundraising in October 2020, is already delivering.”

  Andrew Newland, ANGLE plc, Prostate cancer, Solid tumors, United Kingdom